Condition
Unverricht-Lundborg Disease
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 3 (3)
Trial Status
Completed2
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06593951Recruiting
Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)
NCT00368251Phase 3CompletedPrimary
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
NCT03351569Phase 3UnknownPrimary
Intravenous Immunoglobulin for Unverricht-Lundborg Disease.
NCT00357669Phase 3CompletedPrimary
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
Showing all 4 trials